» Articles » PMID: 30876951

Sustained Release Silk Fibroin Discs: Antibody and Protein Delivery for HIV Prevention

Overview
Specialty Pharmacology
Date 2019 Mar 17
PMID 30876951
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

With almost 2 million new HIV infections worldwide each year, the prevention of HIV infection is critical for stopping the pandemic. The only approved form of pre-exposure prophylaxis is a costly daily pill, and it is recognized that several options will be needed to provide protection to the various affected communities around the world. In particular, many at-risk people would benefit from a prevention method that is simple to use and does not require medical intervention or a strict daily regimen. We show that silk fibroin protein can be formulated into insertable discs that encapsulate either an antibody (IgG) or the potent HIV inhibitor 5P12-RANTES. Several formulations were studied, including silk layering, water vapor annealing and methanol treatment to stabilize the protein cargo and impact the release kinetics over weeks. In the case of IgG, high concentrations were released over a short time using methanol treatment, with more sustained results with the use of water vapor annealing and layering during device fabrication. For 5P12-RANTES, sustained release was obtained for 31 days using water vapor annealing. Further, we show that the released inhibitor 5P12-RANTES was functional both in vitro and in ex vivo colorectal tissue. This work shows that silk fibroin discs can be developed into formidable tools to prevent HIV infection.

Citing Articles

Treatment with the CCR5 antagonist OB-002 reduces lung pathology, but does not prevent disease in a Syrian hamster model of SARS-CoV-2 infection.

Warner B, Vendramelli R, Boese A, Audet J, Tailor N, Meilleur C PLoS One. 2025; 20(2):e0316952.

PMID: 39908288 PMC: 11798459. DOI: 10.1371/journal.pone.0316952.


Sustained Delivery of the Antiviral Protein Griffithsin and Its Adhesion to a Biological Surface by a Silk Fibroin Scaffold.

Guan W, Zhang N, Bains A, Martinez A, LiWang P Materials (Basel). 2023; 16(16).

PMID: 37629837 PMC: 10456748. DOI: 10.3390/ma16165547.


Actively separated microneedle patch for sustained-release of growth hormone to treat growth hormone deficiency.

Yang L, Liu Q, Wang X, Gao N, Li X, Chen H Acta Pharm Sin B. 2023; 13(1):344-358.

PMID: 36815043 PMC: 9939297. DOI: 10.1016/j.apsb.2022.04.015.


Biomaterials and Extracellular Vesicle Delivery: Current Status, Applications and Challenges.

Leung K, Shirazi S, Cooper L, Ravindran S Cells. 2022; 11(18).

PMID: 36139426 PMC: 9497093. DOI: 10.3390/cells11182851.


Enhancing influenza vaccine immunogenicity and efficacy through infection mimicry using silk microneedles.

Stinson J, Boopathy A, Cieslewicz B, Zhang Y, Hartman N, Miller D Vaccine. 2021; 39(38):5410-5421.

PMID: 34391593 PMC: 8405573. DOI: 10.1016/j.vaccine.2021.07.064.


References
1.
Yavuz B, Zeki J, Coburn J, Ikegaki N, Levitin D, Kaplan D . In vitro and in vivo evaluation of etoposide - silk wafers for neuroblastoma treatment. J Control Release. 2018; 285:162-171. PMC: 6098973. DOI: 10.1016/j.jconrel.2018.07.002. View

2.
Girard L, Birse K, Holm J, Gajer P, Humphrys M, Garber D . Impact of the griffithsin anti-HIV microbicide and placebo gels on the rectal mucosal proteome and microbiome in non-human primates. Sci Rep. 2018; 8(1):8059. PMC: 5966460. DOI: 10.1038/s41598-018-26313-8. View

3.
Wei X, Decker J, Liu H, Zhang Z, Arani R, Michael Kilby J . Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother. 2002; 46(6):1896-905. PMC: 127242. DOI: 10.1128/AAC.46.6.1896-1905.2002. View

4.
Jewell M, Daunch W, Bengtson B, Mortarino E . The development of SERI® Surgical Scaffold, an engineered biological scaffold. Ann N Y Acad Sci. 2015; 1358:44-55. DOI: 10.1111/nyas.12886. View

5.
Gautam R, Nishimura Y, Gaughan N, Gazumyan A, Schoofs T, Buckler-White A . A single injection of crystallizable fragment domain-modified antibodies elicits durable protection from SHIV infection. Nat Med. 2018; 24(5):610-616. PMC: 5989326. DOI: 10.1038/s41591-018-0001-2. View